One important advancement in medical therapy is the use of GLP-1 medications, such as tirzepatide and Ozempic (semaglutide GLP-1)
Oral small-molecule GLP-1 and multi-agonist pipelines are redefining competitive intensity, as pharmaceutical companies seek therapies that can combine injectable-like clinical performance with easier dosing, scalable manufacturing, and broader use across primary care, pharmacy and telehealth channels
Barriers to availability of GLP-1 agonists
The prediction of subcellular localization was performed by compiling results obtained from various softwares as Predotar, TargetP, and Wolfpsort
Comprehensive safety studies spanning six months in rats (up to 100 mg/kg/day) and nine months in cynomolgus monkeys (up to 50 mg/kg/day) revealed no adverse findings, with NOAEL reaching the highest applied dosages